Investigators: Charles S. Grob, MD, and Russell E. Poland, PhD
Harbor-UCLA Medical Center – Torrance, California, USA
Sponsor: MAPS, Harbor/UCLA
Contact: ,
FDA-approved Phase 1 dose-response safety study .25 to 2.25 mg/kg, dose administration phase completed, data for .25 to .75 mg/kg published. Data for 1.00 to 2.25 mg/kg being analysed for publication.
Also see the details and references page, and view the video.
